Abstract:
본 발명은 일본 뇌염 바이러스 유전자 prME을 발현하는 돼지 아데노바이러스 3형(porcine adenovirus type 3: PAV3) 재조합 벡터(pPAV3E3-prME: 수탁번호 제KCTC 10376BP호), 및 그로부터 발현되는 재조합 돼지 아데노바이러스 3형(PAV3E3-prME) 및 일본 뇌염에 대한 백신으로서의 그의 용도에 관한 것이다.
Abstract:
PURPOSE: Recombinant porcine adenovirus type 3 expressing Japanese encephalitis virus gene prME and use thereof are provided, thereby inducing immunity to Japanese encephalitis virus in human, and improving stability of the vaccine by using adenovirus. CONSTITUTION: A recombinant vector of porcine adenovirus type 3 expressing Japanese encephalitis virus gene prME, pPAV3E3-prME(KCTC 10376BP), is prepared by removing E3 gene of porcine adenovirus type 3, and inserting the Japanese encephalitis virus gene prME under the control of E3 promoter, wherein the Japanese encephalitis virus gene prME has the nucleotide sequence set forth in SEQ ID NO: 1. A host cell transformed with the recombinant vector pPAV3E3-prME(KCTC 10376BP) is provided. The recombinant porcine adenovirus type 3 expressing Japanese encephalitis virus gene prME(PAV3E3-prME) is obtained by culturing the transformed host cell. A vaccine for Japanese encephalitis virus comprises the recombinant porcine adenovirus type 3 expressing Japanese encephalitis virus gene prME.
Abstract translation:目的:提供3型表达日本脑炎病毒基因prME的重组猪腺病毒及其用途,从而诱导人体对日本脑炎病毒的免疫,并通过使用腺病毒提高疫苗的稳定性。 构成:通过除去3型猪腺病毒的E3基因,并将日本脑炎病毒基因prME置于E3的控制下,制备3型表达日本脑炎病毒基因prME,pPAV3E3-prME(KCTC 10376BP)的猪腺病毒重组载体 启动子,其中日本脑炎病毒基因prME具有SEQ ID NO:1所示的核苷酸序列。提供用重组载体pPAV3E3-prME(KCTC 10376BP)转化的宿主细胞。 通过培养转化的宿主细胞获得表达日本脑炎病毒基因prME(PAV3E3-prME)的重组猪腺病毒3型。 日本脑炎病毒疫苗包含3型表达日本脑炎病毒基因prME的重组猪腺病毒。
Abstract:
PURPOSE: A DNA vaccine using Japanese encephalitis virus and porcine immunoregulatory genes, and a method for using the same are provided, which DNA vaccine selectively uses strong cellular immunity and humoral immunity by change of genetic manipulation or administration pathway, minimizes side-effects by diluents in the administration area, inhibits pathogenicity recovering shown in live vaccine, and minimizes lowering of immunity when it is used with other disease vaccines. CONSTITUTION: The DNA vaccine using Japanese encephalitis virus and porcine immunoregulatory genes comprises a recombinant plasmid pSLIA-prME(KCTC 10378BP) containing Japanese encephalitis virus gene prME and a recombinant plasmid pSLIA-NS1(KCTC 10379BP) containing porcine immunoregulatory gene NS1, and further comprises a recombinant plasmid pSLIA-PIL-2(KCTC 10380) containing porcine interleukin-2 gene PIL-2, wherein the DNA vaccine is subcutaneously administered to pigs through the pig's tail. The method for preventing the infection of Japanese encephalitis virus comprises administering the recombinant plasmids pSLIIA-prME and pSLIA-NS1 into pigs, wherein the recombinant plasmid pSLIA-PIL-2 may be further administered into pigs.